Bionxt Solutions Gains Key Patent for Sublingual Drug Delivery Technology

Bionxt Solutions, a Canadian life sciences company, has achieved a significant regulatory milestone with the Eurasian Patent Organization (EAPO) granting approval for a core patent covering sublingual drug delivery. This development represents substantial progress toward the company’s objective of treating Multiple Sclerosis using an innovative thin-film medication format.

The patent notification received Thursday confirms that Bionxt’s application for sublingual administration of cancer medications targeting autoimmune and neurodegenerative conditions has met all necessary requirements. Following payment of publication fees scheduled for this week, formal patent protection will extend across eight member states with a combined population exceeding 200 million.

Patent coverage now encompasses Armenia, Azerbaijan, Belarus, Kazakhstan, Kyrgyzstan, Russia, Tajikistan, Read more...